Table of Contents Table of Contents
Previous Page  55 / 328 Next Page
Information
Show Menu
Previous Page 55 / 328 Next Page
Page Background

PROFILE OF AOAC EXPERT REVIEW PANEL FOR SPDS – CHONDROITIN, PDE5 INHIBITORS, & ANTHOCYANIN 

METHODS

ERP Name 

AOAC Expert Review Panel for Dietary Supplements –

Chondroitin, PDE5 Inhibitors, and Anthocyanin Methods 

Chair(s)

Brian Schaneberg (Starbucks)

ERP Formed: 

2015 

Number of 

Methods Adopted 

1 as First Action 

status 

Number of Methods 

Recommended 

None Yet

Scope: 

Review and adopt methods resulting from sole source submission of methods for dietary supplements

Roster 

Chondroitin: 

1.

Brian Schaneberg, Starbucks 

(Chair) 

2.

Jana Hildreth, Synutra Pure  

3.

Martha Jennens, Covance 

4.

Phillip Koerner,Phenomenex;  

5.

Tom Phillips, State of MD;  

6.

Curtis Phinney, Consultant; 

7.

Kelly Reins, Consultant;  

8.

John Spzylka, Merieux 

NutriSciences; Aniko Solyom, 

GAAS Corporation;  

9.

Darryl Sullivan, Covance  

10.

Liton Roy, Sancillo and Company;  

11.

Nour Edine ES‐SAFI, Mohammad V 

University Rabat 

PDE5 Inhibitors:  

1.

Brian Schaneberg, Starbucks 

(Chair);  

2.

Phil Koerner, Phenomenex;  

3.

Katerina Mastovska, Covance;  

4.

Tom Phillips, State of MD;  

5.

Fenhong Song, FDA;  

6.

John Spzylka, Mérieux 

NutriSciences;  

7.

Darryl Sullivan, Covance.  

8.

Teresa Cain, FDA;  

9.

Liton Roy, Sancilio;  

10.

Jerry Zweigenbaum, Agilent. 

Anthocyanins: 

1.

Brian Schaneberg, Starbucks 

(Chair);  

2.

Phil Koerner, Phenomenex;  

3.

Jungmin Lee, USDA;  

4.

Melissa Phillips, NIST; 

5.

Martha Jennens, Covance;  

6.

Tom Phillips, State of MD;  

7.

Aniko Solyom, GAAS Analytics;  

8.

John Spzylka, Mérieux 

NutriSciences;  

9.

Darryl Sullivan, Covance  

10.

Nour Eddine ES‐SAFI, Mohammed 

V University;  

11.

Liton Roy, Sancilio and Company;  

12.

Jerry Zweigenbaum, Agilent 

Technical 

Documents 

created/used 

SMPRs  for Chondroitin, PDE5 Inhibitors, and Anthocyanins 

OMA Appendix K 

Methods 

Adopted 

First Action 

and Final 

Action 

status

AOAC 2015.11 – Chondroitin 

AOAC 2015.12  ‐ PDE5 inhibitors 

Final Action Methods Recommended 

Additional Input 

Awards/Recognitions 

ERP PROFILE SUMMARIES

54